1. Home
  2. INTT vs SKYE Comparison

INTT vs SKYE Comparison

Compare INTT & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo inTest Corporation

INTT

inTest Corporation

HOLD

Current Price

$10.71

Market Cap

139.2M

Sector

Technology

ML Signal

HOLD

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

HOLD

Current Price

$1.74

Market Cap

9.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INTT
SKYE
Founded
1981
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
139.2M
9.0M
IPO Year
1997
2013

Fundamental Metrics

Financial Performance
Metric
INTT
SKYE
Price
$10.71
$1.74
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
3
Target Price
$13.50
$15.00
AVG Volume (30 Days)
94.9K
81.7K
Earning Date
05-05-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.06
N/A
Revenue
$66,801,000.00
N/A
Revenue This Year
$15.82
N/A
Revenue Next Year
$9.10
N/A
P/E Ratio
$179.42
N/A
Revenue Growth
66.06
N/A
52 Week Low
$7.07
$0.26
52 Week High
$20.00
$4.99

Technical Indicators

Market Signals
Indicator
INTT
SKYE
Relative Strength Index (RSI) 35.57 55.17
Support Level $10.32 $1.64
Resistance Level $10.88 $2.28
Average True Range (ATR) 0.48 0.22
MACD 0.04 -0.06
Stochastic Oscillator 7.28 32.67

Price Performance

Historical Comparison
INTT
SKYE

About INTT inTest Corporation

inTest Corp is a supplier of test and process technology solutions for use in manufacturing and testing across a wide range of markets, including Semi, Auto/EV, Defense/Aerospace, Industrial, Life Sciences, Safety/Security, and Other. The Company has three operating segments, which are also its reportable segments and reporting units: Electronic Test, which generates the majority of its revenue and includes semiconductor test equipment, flying probe, and in-circuit testers; Environmental Technologies, which includes thermal test, process, and storage products; and Process Technologies, which includes induction heating and video imaging products. The Company generates the maximum revenue from the U.S.

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: